Clinical Trials

Click Here for General Info About Clinical Trials

Trials at Arkansas Urology

A clinical trial is a research study that finds new ways to treat a disease. The Arkansas Urology Research Center (AURC)  participates in several clinical research trials to offer therapies to our patients that are not yet available at other local practices or clinics in Arkansas. These clinical trials are available to men and women of all ages.

You’ll find a few studies that we are actively enrolling our patients in listed below. We have additional studies not listed. Please contact the AURC at 501-219-8900 x 2002 if you are interested in learning more about these studies and/or other research opportunities.

Janssen LogoMetastatic Castration-Sensitive Prostate Cancer

CLICK HERE TO LEARN MORE ABOUT TRIAL

LIBERTAS-A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide with Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) following PSA Response in Participants with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

GREGOR DIAGNOSTICS  *Semen Collection at the Time of Prostate Biopsy

CLICK HERE TO LEARN ABOUT SEMEN COLLECTION FOR PROSTATE CANCER DIAGNOSTICS

Blood Collection at the Time of Prostate Biopsy

The purpose of this research is to see if a new, experimental blood test might help men with prostate cancer who are on active surveillance need fewer prostate needle biopsies.

A blood sample is collected in Little Rock at the lab or at the surgery center prior to your biopsy.

Myovant Sciences

Observational Study of Patients of Being Treated ORGOVYX

Click Here to View the OPTYX Brochure

OPTYX-A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX

 

Janssen Logo

High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)

CLICK HERE TO LEARN MORE ABOUT TRIAL

SUNRISE 3-Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants with BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)

Janssen LogoHigh-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)

CLICK HERE TO LEARN MORE ABOUT TRIAL

SUNRISE-5-A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator’s Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

Janssen LogoIntermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC)

CLICK HERE TO LEARN MORE ABOUT TRIAL

What is FGFR?

MOONRISE-1-A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations

Janssen Logo

Muscle Invasive Bladder Cancer

CLICK HERE TO LEARN MORE ABOUT TRIAL

SUNRISE-4-Janssen is conducting a Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Scheduled for Radical Cystectomy and Are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy.

High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)

CLICK HERE TO LEARN MORE ABOUT TRIAL

UR001-A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UGN-301 (zalifrelimab) Administered Intravesically as Monotherapy and in Combination with Other Agents in Patients with Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)

CLICK HERE TO LEARN MORE ABOUT TRIAL

PATAPSCO-This is an open-label, single-arm, multi-center, Phase IIIb US study exploring the combination of durvalumab and BCG (induction and maintenance) in participants with high-risk NMIBC

The following trials are single-arm, prospective studies assessing semen quality after treatment with the Optilume DCB in men between 22 and 65 years of age.

 

BPH    Click Here to View Optilume Info and Video

PEAK-Safety and Effectiveness of the Optilume® BPH Catheter System in a Post-Market Study

Urethral Stricture  Click Here to View the Optilume Drug Coated Balloon Video

STREAM-Optilume PoST AppRoval Clinical Evaluation of Andrology ParaMeters

 

A Phase 2 Study of IW‑3300 for the Treatment of Bladder Pain in Subjects with Interstitial Cystitis/Bladder                  Pain Syndrome

Click Here to View Video About the Trial

 

Urge Urinary Incontinence

A Real World Study of eCoin® for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE)

Click Here to Review  the eCoin Info and View Video

eCoin® is the first FDA-approved tibial stimulator device for Urge Urinary Incontinence (UUI). The coin-sized device is placed under the skin, near the ankle during a safe and minimally invasive procedure.

 

Detection of Clear Cell Renal Cell Carcinoma

An Expanded Access Program for the non-invasive detection of clear cell renal cell carcinoma (ccRCC) in patients with renal masses utilizing 89Zirconium-labelled girentuximab (89Zr-DFO-girentuximab)

Click Here to View a Video About Telix

Click Here for the Patient Brochure

Find A Physician
Powered by Lapero